US Obesity Rates Plummet Amid Surge in Weight-Loss Medications
A new study by Gallup has revealed that the United States has seen an alarming decline in obesity rates, falling from nearly 40% in 2022 to 37% last year. The remarkable drop is attributed largely to a rise in the use of prescription weight-loss medications, including GLP-1 (glucagon-like peptide-1) injectables such as Ozempic and Wegovy.
According to Gallup's National Health and Well-Being Index survey, which polled nearly 17,000 adults across the country, the percentage of Americans using these blockbuster medications for weight loss has surged from 5.8% in February last year to a staggering 12.4% today. The resulting decline in obesity rates translates into around 8 million fewer obese adults nationwide.
However, this trend is offset by an alarming rise in diabetes rates, which have hit an all-time high of 13.8% in the same period, up from 13.4% last year and 12.8% two years ago. The disparity between declining obesity and unchanged diabetes rates suggests that several factors are at play.
While it is true that obesity increases one's risk of developing type 2 diabetes fourfold, not everyone who is obese will contract the condition, and some non-obese individuals may be diagnosed with diabetes as well. Moreover, diabetes is a chronic illness, which means that short-term reductions in obesity rates won't necessarily translate to decreased rates of diabetes.
Demographically, the survey also revealed striking differences in weight-loss medication use between men and women, as well as across age groups. While both genders have seen their usage rates double over the past year, women are using these medications at higher rates than men. The most significant reductions in obesity were observed among people aged 40-64, a demographic that also exhibits the highest rate of GLP-1 drug use.
Overall, these findings suggest that the United States is experiencing an unprecedented shift towards weight-loss medication adoption, which may have both positive and concerning implications for public health.
A new study by Gallup has revealed that the United States has seen an alarming decline in obesity rates, falling from nearly 40% in 2022 to 37% last year. The remarkable drop is attributed largely to a rise in the use of prescription weight-loss medications, including GLP-1 (glucagon-like peptide-1) injectables such as Ozempic and Wegovy.
According to Gallup's National Health and Well-Being Index survey, which polled nearly 17,000 adults across the country, the percentage of Americans using these blockbuster medications for weight loss has surged from 5.8% in February last year to a staggering 12.4% today. The resulting decline in obesity rates translates into around 8 million fewer obese adults nationwide.
However, this trend is offset by an alarming rise in diabetes rates, which have hit an all-time high of 13.8% in the same period, up from 13.4% last year and 12.8% two years ago. The disparity between declining obesity and unchanged diabetes rates suggests that several factors are at play.
While it is true that obesity increases one's risk of developing type 2 diabetes fourfold, not everyone who is obese will contract the condition, and some non-obese individuals may be diagnosed with diabetes as well. Moreover, diabetes is a chronic illness, which means that short-term reductions in obesity rates won't necessarily translate to decreased rates of diabetes.
Demographically, the survey also revealed striking differences in weight-loss medication use between men and women, as well as across age groups. While both genders have seen their usage rates double over the past year, women are using these medications at higher rates than men. The most significant reductions in obesity were observed among people aged 40-64, a demographic that also exhibits the highest rate of GLP-1 drug use.
Overall, these findings suggest that the United States is experiencing an unprecedented shift towards weight-loss medication adoption, which may have both positive and concerning implications for public health.